Congress advances HR 466 to reauthorize ALS therapy access programs

Where This Stands

Introduced

Committee

Floor Vote

Passed

Signed

Currently in_committee. The next step in the legislative lifecycle is Floor Vote.

Last action

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.Jul 23, 2026

Lead sponsor

Scott Fitzgerald

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

This legislation ensures the continuation of federal infrastructure and funding streams dedicated to accelerating the development and availability of therapies for patients diagnosed with ALS, a progressive neurodegenerative disease.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

ALS patients

The bill reauthorizes programs that facilitate access to experimental therapies for those living with the disease.

Medical research community

The legislation provides the federal framework and funding support for ongoing ALS therapy development.

What changed

Current stage: in_committee.

What's next

Floor Vote.

Summary

The Accelerating Access to Critical Therapies for ALS Act of 2026 has been received in the Senate and placed on the legislative calendar for consideration. This measure continues federal support for programs designed to improve access to experimental treatments for individuals living with Amyotrophic Lateral Sclerosis (ALS).

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

This legislation ensures the continuation of federal infrastructure and funding streams dedicated to accelerating the development and availability of therapies for patients diagnosed with ALS, a progressive neurodegenerative disease.

Frequently Asked Questions

What does this bill do?

It reauthorizes federal programs aimed at accelerating access to critical therapies for patients with ALS.

What is the current status of the bill?

As of April 6, 2026, the bill has been received in the Senate and placed on the legislative calendar.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Legislative Continuity

The bill serves as a reauthorization, indicating a federal commitment to maintaining existing ALS research infrastructure rather than creating new programs.

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026